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Cardiac pathologies are among the leading causes ofmortality andmorbidity in industrialized countries, withmyocardial infarction
(MI) representing one of the major conditions leading to heart failure (HF). Hitherto, the development of consistent, stable, and
reproducible models of closed-chest MI in large animals, meeting the clinical realism of a patient with HF subsequent to chronic
ischemic necrosis, has not been successful. We hereby report the design and ensuing application of a novel porcine experimental
model of closed-chest chronic ischemia suitable for biomedical research, mimicking post-MI HF. We also emphasize the key
procedural steps involved in replicating this unprecedented model, from femoral artery and vein catheterization to MI induction
by permanent occlusion of the left anterior descending coronary artery through superselective deployment of platinum-nylon
coils, as well as endomyocardial biopsy sampling for histologic analysis and cell harvesting. Our model could indeed represent a
valuable contribution and tool for translational research, providing precious insights to understand and overcome themany hurdles
concerning, and currently quenching, the preclinical stepsmandatory for the clinical translation of new cardiovascular technologies
for personalized HF treatments.
1. Introduction
Cardiac pathologies are among the leading causes of mor-
tality and morbidity in industrialized countries, with heart
failure (HF) representing the final common pathway for
many diseases that affect the heart and defining a syndrome
characterized by inadequate performance of the heart that
negatively affects whole body blood supply [1]. Myocardial
infarction (MI) is one of the major conditions leading to
HF, having an ominous impact on public health in terms
of mortality and morbidity [2]. The hemodynamic overload
generated by MI imposes mechanical and neurohumoral
modifications on cardiac walls, triggering complex biological
responses that culminate in tissue remodeling. This response
initially starts as compensatory left ventricular hypertrophy
but eventually evolves towards maladaptive remodeling,
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possibly triggering transition to HF. The cascade of events
that begins with cardiac hypertrophy, attempting to set on a
compensatory response and finally leading to HF, is charac-
terized by contractile dysfunction and cell death of stressed
cardiomyocytes, reduced capillary density, inflammation and
fibrosis [3]. To date available medical treatments aim more
at preserving residual, albeit compromised, cardiac function
rather than at restoring lost functions. Besides, available drug
therapies act by decreasing cardiac workload by reducing
heart rate and blood pressure (such as𝛽-blockers), preserving
blood flow in coronaries (such as nitrates), and by blocking
or reversing the remodeling process (such as angiotensin-
converting enzyme (ACE) inhibitors), while not addressing
the specific issue of recovering the loss of function due to
massive muscular death. Even cardiac surgery remains a
palliative management, not always suitable for catastrophic
events like large myocardial damage due to huge infarction
and cell demise.
However, all research approaches focusing on the im-
provement of cardiac function by cell therapy have hitherto
encountered only incomplete success and generated con-
flicting results with no clear evidence of heart regeneration
potential, which is mainly due to unsolved issues related to
low survival and engraftment rate of injected cells, as well
as the occurrence of complications such as inflammation or
fibrosis [4]. In that sense, the scientific community has now
to take a step back as the clinical outcome highlighted by
the most recent clinical trials has only partially mirrored
the expected results based on preclinical animal models, in
terms of actual engraftment, survival, differentiation, and
functional recovery.
Thus, the development of a consistent, stable, and repro-
ducible model of closed-chest MI and cell delivery is manda-
tory as an efficient and realistic tool for the preclinical evalu-
ation of cell therapy procedures. Nowadays, in the scholarly
literature, several in vivo animal models reproducing HF are
available as a result of genetic modifications, surgical liga-
ture of the coronary arteries (with or without reperfusion),
microembolization, cryoinjuries to the epicardium, electrical
stimulation at a rapid pace, modifications of load, or toxic
pharmacological treatments [5–10]. All these models have
certainly allowed us to improve our mechanistic knowledge,
but they do not go far enough in meeting the clinical
reality of a patient with HF subsequent to chronic ischemia.
Indeed, small animal models such as rodents have provided
significant insights into human cardiac pathophysiology.
Specifically, rodent and human hearts are greatly different in
their dimension, structure, heart rate, oxygen consumption,
regional and global contractility, protein expression, and even
in resident stemcell populations [11], with the consequent and
clear need for models of HF in large animals. The emergence
of such large animal models in cardiovascular research fields
such as MI, HF, valvular disease, heart transplantation, and
ventricular assist devices (VAD) reflects the close similarity
of these animals to human anatomy and physiology. The
size of pigs (e.g., female Landrace pigs, weighing 30–35 kg,
aged 3–12 months) allows the use of surgical equipment and
imaging modalities similar to those used in humans, aiming
at reproducing a real clinical situation with the employment
of human-sized instruments while enabling the development
and application of a unique model close to the clinical reality
of a patient with HF.
In the light of this, our aim was to devise and apply a
novel porcine closed-chest experimental model for biomed-
ical research, describing how to perform a full procedure
from femoral artery and vein catheterization to MI creation
by minimally invasive transcatheter permanent coronary
occlusion at the level of the left anterior descending artery
(LAD) with selective deployment of intraluminal coils. We
also describe transcatheter endomyocardial bioptic sample
collection in order to isolate, characterize, and expand autol-
ogous resident cardiac progenitor cells [12], representing the
basis for the clinical translation of new possible protocols
for regenerative medicine. Results from this report aim
at proposing a consistent, stable, reproducible, and, most
importantly, clinically relevant model of closed-chest MI
and ensuing HF, resembling more realistically the medical
history of a patient with this condition, and thus representing
a more accurate pathophysiological model to test possible
cardiac progenitor cell-based technologies for personalized
HF treatments closer to clinical translation.
2. Materials and Methods
2.1. In Vivo Experimental Protocol. All animals were handled
in compliance with the European Convention on Animal
Care and received humane care in accordance with the Prin-
ciples of Laboratory Animal Care and the Guide for the Care
and Use of Laboratory Animals. The experimental protocol
was approved by local authorities and by the bioethical
committee of the Catholic University, Rome, Italy (Protocol
CESA/P/52/2012-13/12/2012).
2.2. Animal Preparation and Anesthesia. Experimental pre-
paration and surgical protocol were performed under sterile
conditions. Atropine (0.02mg/kg IM), ketamine (15mg/kg
IM), and diazepam (0.1mg/kg IM) were used for premedi-
cation, and intravenous access was obtained with a 21- or 22-
Gauge needle in the ear vein. Anesthesia was induced by IV
injection of ketamine (35mg/kg) and diazepam (0.1mg/kg).
All animals were intubated with an endotracheal tube of
5 to 7mm internal diameter, and general anesthesia was
maintained with 1% to 2% isoflurane supplemented with
oxygen, both supplied by an Aliseo mechanical ventilator
(Datex Ohmeda, General Electric, Fairfield, CN, USA) and
a constant rate IV infusion of propofol at 6mg/kg/h for
the first two hours and then at 4mg/kg. Muscle relaxation
was obtained with a constant rate IV infusion of atracurium
besylate (0.5mg/kg). Ventilator parameters were set accord-
ing to each animal body weight (tidal volume 10mL/kg,
respiratory rate 16/minute, I/E 1 : 2, FiO2 40%, heart rate
70/130 bpm, SBP 110–120/70–80mmHg, central venous pres-
sure 4–10mmHg). During the anesthesia we used a IV
infusion of Ringer Lactate crystalloid solution of 10mL/kg.
In order to prevent infection, we administered enrofloxacin
(5mg/kg qd IM for 5 days), whereas for the intra- and
postoperatory pain relief we used tramadol at 2/4mg/kg bid
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Figure 1: ((a) and (b)) Ventricular biopsies obtained using a standard clinical cardiac bioptome introduced through a 7-French sheath. (c)
Evidence of the intraluminal platinum-nylon coil (Axium,Covidien,Mansfield,MA,USA) at 1month followup (distal left anterior descending
(LAD) represented by the star). (d) Evidence of the coronary lumen at 1 month highlighting the segment of the coronary vessel distal to the
occluded segment (distal LAD represented by the star).
IM/EV for the first 48 h, followed by ketoprofen: 2mg/kg
qd IM for further 3 days. Before starting all the procedures
(about 30 minutes prior to the intervention) an IV infusion
of 1.0–2.5mg/kg amiodarone was started in order to prevent
possible ventricular arrhythmias, and 2000 IU heparin IV
was administered in order to avoid thromboembolic phe-
nomena.
2.3. Ventriculography, Bioptic Sampling, and Coil Deployment.
The right femoral artery was willingly punctured in all
animals according to Seldinger and cannulated with a short
5-French sheath exchanged for a 90 cm 7-French sheath
(Cordis, Miami, FL, USA). Left ventriculography was per-
formed in a right anterior oblique projection, with injection
of dye through either a 5-French pigtail catheter (Boston
Scientific, Natick, MA, USA), a 5-French Amplatz Right 1
diagnostic catheter (Boston Scientific), deployed by means of
a 300 cm 0.035󸀠󸀠 angiographic guide wire (Boston Scientific),
or the 7-French sheath. Then, endomyocardial biopsy was
performed aiming at the interventricular septum with a 7-
French device (BiPal, Cordis). After obtaining a suitable
number of endomyocardial samples (5 to 7 per animal, each
weighing from 10 to 50mg, see Figure 1), the bioptome was
exchanged for an Amplatz Right 1 or Amplatz Left 1 Judkins
Right guiding catheters, which were used to cannulate the
left coronary artery for selective coronary arteriography
and coil deployment. A 0.014󸀠󸀠 J-tipped floppy angioplasty
guide wire (ChoICE PT floppy, Boston Scientific) was then
inserted into the LAD under fluoroscopic guidance, and
coronary occlusion was achieved by deploying one or more
4.0 × 10mm platinum-nylon microcoils (Axium, Covidien,
Mansfield, MA, US) distally to the ostium of the first major
diagonal branch. To further ensure that the occlusion was
permanent, 20mg of protamine was administered IV after
deployment of the coil. Complete cessation of flow into the
distal LAD was then confirmed by angiography in all cases
(Figure 2). Amiodarone was discontinued 30 minutes after
the evidence of ischemia, even if only one case of significant
arrhythmias occurred. After all the procedures animals were
gradually weaned from anesthesia and allowed to recover in
specific single cages. For postoperatory pain relief we used
tramadol at 2/4mg/kg bid IM/IV for the first 48 hours,
followed by ketoprofen: 2mg/kg qd IM for further 3 days.
All animals were monitored (4 times/day) and handled in
compliance with the European Convention on Animal Care
and received humane care in accordance with the Principles
of Laboratory Animal Care and the Guide for the Care and
Use of Laboratory Animals.
2.4. Electrocardiography and Echocardiography. To assess for
signs of acute myocardial injury, continuous monitoring by
electrocardiography (ECG) was performed. Changes in 12-
lead ECGwere also appraised to confirmongoingMI, record-
ing at 25mm/s, 40Hz, and 10mm/mV in all anesthetized
and immobilized animals in a supine position. Catheters
and sheaths were removed, with hemostasis achieved with
manual compression, while transthoracic echocardiography
(1 hour after-procedure) was performed to evaluate wall
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Figure 2: Coronary angiography of the occlusion of the mid tract of the left anterior descending coronary leading to myocardial infarction
after deploying an intraluminal platinum-nylon coil (Axium, Covidien, Mansfield, MA, USA) at (a) 1 month followup (star represents the
coil), with retrograde collateral flow from the left circumflex (b). Follow-up ventriculography showing the diastolic (c) and systolic (d) phases.
Arrowheads represent the akinetic segments.
motion abnormalities, confirming in real time the pres-
ence of hypokinesia/akinesia of the anterior-lateral wall.
Echocardiographic evaluation was performed at baseline, 1
hour after the occlusion, and then at 1-week and 1-month
followup. Animals were investigated both in a right and
left lateral positions. An experienced cardiologist performed
all echocardiographic studies. A commercially available CX-
50 machine (Philips, Andover, MA, USA), equipped with
a 1–5MHz probe (S5-1 PureWave sector array), was used
for all examinations. Two-dimensional and M-mode data
were acquired in parasternal long- and short-axis views at
the level of papillary muscles and in apical four-chamber
view. At least three consecutive beats were acquired and
digitally recorded for off-line analysis performed by two
experienced cardiologists with proprietary software (Philips).
Left ventricular (LV) diameters, thicknesses, ejection fraction
(LVEF), fractional shortening (LVFS), and LV volumes were
obtained. The euthanasia was obtained after 30 days with
the administration of Tanax (0.3mL/kg IV; Intervet Italia,
Segrate, Italy).
Hearts were explanted, rinsed 8–10 times with saline
solution for a total of 5minutes, prepared by surgical opening
of the right and left atria and immediately submerged in
a medical grade formaldehyde-buffered solution in sterile
conditions for histological and immunohistochemical assess-
ment.
2.5. Tissue Processing and Histology. After sacrifice, hearts
were harvested and fixed with formaldehyde 4% (Kaltek,
Padua, Italy) for 48 hours. The presence and the location
of the infarct area were assessed by two expert clinical
pathologists through macroscopic examination. Paraffin sec-
tions (2𝜇m) were then obtained from fixed hearts (PM2255
microtome, Leica, Solms, Germany) and stainedwith haema-
toxylin/eosin in the automated station St 5020 (Leica)
to microscopically analyse the myocardial tissue. Subse-
quently, tissue sections were stainedwithMasson’s Trichrome
(Menarini, Parma, Italy, cat. N∘ 04010802), and images were
acquired by a DSIGHT Fluo microscope (Menarini).
3. Results
3.1. Functional Evaluation. One out of 5 animals (20%)
showed ventricular fibrillation immediately after permanent
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Figure 3: (A) Echocardiography at 1 month: M-mode image of left ventricle (LV); the arrow points at the anterior interventricular septum,
which appears severely hypokinetic/akinetic, in comparison with the posterior wall. (B) Two-dimensional parasternal long axis; the LV apex
appears remodeled and aneurysmatic (arrow), and wall thickness is markedly reduced in comparison with the basal segment. LA: left atrium.
Follow-up ventriculography (1 month), with magnified views, showing a remodeled and aneurysmatic LV apex, in the right oblique (C) and
anteroposterior (D) views.
LAD occlusion, and in this case resuscitation was achieved
with repeated adrenaline boluses (10 mcg/kg IV) and a single
biphasic DC shock at 200 Joules. Heart rates were detected
at baseline (79.7 ± 3.5 bpm), soon after the occlusion (100.1 ±
7.3 bpm) and during all the phases of chronic HF subsequent
to permanent coronary occlusion (85.3 ± 5.9 bpm). ECG was
performed at baseline, continuously during the intervention
(pre-, intra-, and postcoronary occlusion), at 1 week and at
the end of the experiment confirming in all significant ST-
segment elevation in the acute phase and a necrosis pattern
afterwards.
Coronary occlusion with the subsequent MI resulted in
immediate reduction in LVEF and LVFS, from 62.7 ± 2.3% to
45.3 ± 5.1% and from 33.6 ± 1.6% to 22.1 ± 2.9%, respectively.
Ongoing remodeling of the LV was evident by continued
reduction in LVEF and LVFS over the following 4 weeks
(from45.3± 5.1% to 35.9± 3.2% and from22.1± 2.9% to 18.2±
4.3%, resp.,) and by an increase in LV end-diastolic diameters
and volumes (Table 1). M-mode imaging of left ventricle
showed a severely hypokinetic/akinetic anterior interventric-
ular septum, in comparisonwith the posteriorwall (Figure 3).
Two-dimensional parasternal long-axis view evidenced an
aneurysmatic left ventricular apex, with the distal andmedian
wall thicknesses markedly reduced in comparison with the
basal segment that resulted normokinetic (Figure 3). This
seems to mirror the LV remodeling observed in humans after
a MI.
Coronary angiography (Figure 2) performed at 1 month
highlighted the completeocclusion of the mid tract of
the LAD consequent to the deployment of the intraluminal
platinum-nylon coil. In two out of five animals (20%), selec-
tive coronary angiography of the LAD at 1-month followup
showed a faint retrograde collateral flow from the left cir-
cumflex (Figure 2). Follow-up ventriculography performed
at 1 month confirmed the presence of akinetic segments
corresponding to the lateral wall of LV and a remodeled and
aneurysmatic apex (Figures 2 and 3).
Mortality in this series was 0% likely in reason of the
fact that, after the set-up stage, we always deployed the
platinum-nylon microcoils distally to the ostium of the first
major diagonal branch. Indeed, deployment of the microcoil
proximally to the ostium of the first major diagonal branch
resulted in immediate ventricular fibrillation unresponsive to
pharmacological and/or electrical treatment, in keeping with
prior experiences with very proximal LAD balloon occlusion
[9].
3.2. Histological Analysis. All hearts showed transmural scar
and massive fibrosis consistent with acute coronary occlu-
sion due to thrombosis [13]. The infarct area was white,
shrunken, thin, and firm. The average of total infarct area
corresponds to 31.8 ± 1.5 cm2 (Figure 4). Healed infarcts
displayed a white scar surrounded by small areas with
congestion and vasodilatation. The ventricular wall was
thinned as it appears in transmural infarction. Indeed the
infarcts occupied more than 60% of the LV wall, from
the subendocardial to the epicardial surface. Microscopic
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Table 1: Basal and postacute myocardial infarction echocardiographic data.
Echocardiographic data Basal Post-AMI1 hour
Post-AMI
1 week
Post-AMI
1 month
LV end-diastolic diameter (mm) 41.6 ± 1.7 40.8 ± 1.9 42.8 ± 1.2 46.7 ± 1.3
LV end-systolic diameter (mm) 27.6 ± 1.2 31.7 ± 0.8 33.7 ± 3.3 38.3 ± 1.3
LV end-diastolic volume (mL) 77.1 ± 7.2 73.5 ± 8.2 84.3 ± 8.3 99.9 ± 4.6
LV end-systolic volume (mL) 28.7 ± 3.6 40.2 ± 2.5 47.3 ± 2.6 63.2 ± 5.1
LV ejection fraction (%) 62.7 ± 2.3 45.3 ± 5.1 42.8 ± 1.7 35.9 ± 3.2
LV fractional shortening (%) 33.6 ± 1.6 22.1 ± 2.9 21.2 ± 6.9 18.2 ± 4.3
LV: left ventricle.
(a) (b)
H&E 10x
(c)
Masson’s Trichrome 20x
(d)
Figure 4: (a)Macroscopic analysis of the porcine heart showing the infarcted area, which appears brighter than the rest of themyocardium. (b)
Ventricular wall appears thinned in the area of transmural infarction. (c) Hematoxylin/eosin (H&E) staining of the porcine model showing
the haemorrhagic and the necrotic zones in the infarcted area. Infiltration of granulation tissue and fibroblastic/macrophagic cells is also
observed (10x magnification). (d) Masson’s Trichrome staining on a selected area of the section confirming both fibrotic connective and
granulation tissues (20x magnification).
findings demonstrate the presence of granulation tissue with
a large number of macrophages often engulfed with debris of
the necrotic myocytes and hemosiderin. Fibroblasts actively
producing collagen were found in the area of healing as
well as angiogenesis. Rare eosinophils were also present
within the chronic inflammatory areas. The central area of
infarction showed a small unhealed zone with mummified
myocytes and limited necrosis. Hemorrhagic areas were also
present. Masson’s Trichrome staining confirmed the presence
of fibrotic area evenly distributed in the tissue sections.
Representative images of histology analysis are displayed in
Figure 4.
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4. Discussion
In the last two decades, rapid advances have been made
in understanding genetic, molecular, and pathophysiological
pathways involved in the development and homeostasis of
the mammalian heart, as well as perturbations that may
influence cardiac physiology. Despite all this, to date reliable
animal models, both suitable for research purposes and
closely resembling human heart failure, still do not exist. The
importance to develop such models is based on major lim-
itations that occur particularly with murine in vivo models,
which show relevant physiological differences with human
hearts [11], although very useful and less expensive than large
animals.
Among large animals, pigs are certainly preferred, due
to the collateral coronary circulation and arterial anatomy
very similar to humans and most importantly because it is
even possible to predict the infarct size [14–16]. Moreover,
animal models of HF, as opposed to isolated cells or organs,
permit amore accurate, realistic, and complete analysis of the
physiological effects of cardiac dysfunction,which are of great
importance in the overall HF epiphenomenon.
In this study we have attempted to address the key issue
of creating an animal model of HF which could simplify an
extremely complex and challenging syndrome into manage-
able cardiovascular research questions. Specifically, themajor
novelty of our model lies in the fact that for the first time we
propose a chronic post-MI HF model with a real LV remod-
eling, based on a closed-chest technique [17], combined
with the permanent occlusion of the LAD. This model has
been conceived to allow the possibility of safely performing
afterward a surgical operation such as a VAD implantation
or a stem cells delivery without the jeopardy of a redo proce-
dure, consequently avoiding all related complications such as
surgical adherences, bleeding, and prolonged surgical times.
The present model, once optimized the coil deployment site,
seems also to have the advantage of dramatically reduced
mortality (nihil in our current experience), possibly reducing
also the overall cost of research. The validation of our model
has been confirmed by the histological analysis, showing
pathological features of a 4-week-old MI, very similar to
nonreperfused or delayed-reperfused MI (6 to 12 hours).
Accordingly, other models exploiting a transient coronary
occlusion followed by reperfusion (opposed to our model of
a permanent coronary occlusion) do not reflect the current
clinical practice, in reason of the fact that the vast majority
of patients with acute MI does not receive a reperfusion
therapy before 3 to 4 hours from symptoms onset or does not
receive it at all [9]. Therefore, this technique might help to
more easily mimic the pathophysiology of nonreperfused or
delayed-reperfused MI.
In the future, we envision exploiting further this model
and evaluating whether it can also prove useful and suitable
for cell therapy applications, by obtaining and injecting
autologous cardiac resident stem cells and by implantation of
left VAD (LVAD) without the challenges of a redo procedure.
All research approaches focusing on the improvement of
cardiac function by cell therapy have hitherto encountered
only incomplete success and generated conflicting results
with no clear evidence of heart regeneration potential, which
is mainly due to unsolved issues related to low survival and
engraftment rate of injected cells, as well as the occurrence
of complications such as inflammation or fibrosis [4, 18–20].
In that sense, the scientific community has now to take a
step back as the clinical outcome highlighted by the most
recent clinical trials has only partially mirrored the expected
results based on preclinical animal models, in terms of
actual engraftment, survival, differentiation, and functional
recovery. Thus, the development of a consistent, stable, and
reproducible model of closed-chest MI and biopsy collection
is mandatory as a realistic tool for the preclinical evaluation
of cell therapy procedures.
Despite the obvious impossibility of selecting one single
swine model as the best fitting or performing for all kinds of
research needs, nevertheless compared to current surgical in
vivo models, our approach could represent a new promising
tool for a more realistic clinical translation of novel regener-
ative medicine technologies.
This work has several strengths but also some key lim-
itations. The limited sample size, performance by a team
of highly skilled clinician investigators, veterinarians, and
pathologists, all thoroughly experienced in animal experi-
mental research spanning from small and large sizes, and
use of sophisticated equipments and devices may limit the
external validity of our results. However, we are confident that
applying this model in a similar setting by similarly experi-
enced and skilled operators will yield similarly satisfactory
and precise results.
5. Conclusion
It is clear that an intriguing question concerns the choice
of the animal model balancing researcher’s options between
convenience, cost, physiological applicability, and real cor-
respondence to the original human model. We are also
aware that a unique animal model cannot exist. Despite all
these limitations, large animals still remain the best tool to
investigate severe diseases such as cardiovascular diseases.
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